BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 11858936)

  • 1. PTEN: The down side of PI 3-kinase signalling.
    Leslie NR; Downes CP
    Cell Signal; 2002 Apr; 14(4):285-95. PubMed ID: 11858936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN.
    Downes CP; Bennett D; McConnachie G; Leslie NR; Pass I; MacPhee C; Patel L; Gray A
    Biochem Soc Trans; 2001 Nov; 29(Pt 6):846-51. PubMed ID: 11709086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions.
    Leslie NR; Bennett D; Gray A; Pass I; Hoang-Xuan K; Downes CP
    Biochem J; 2001 Jul; 357(Pt 2):427-35. PubMed ID: 11439092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that SHIP-1 contributes to phosphatidylinositol 3,4,5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors.
    Freeburn RW; Wright KL; Burgess SJ; Astoul E; Cantrell DA; Ward SG
    J Immunol; 2002 Nov; 169(10):5441-50. PubMed ID: 12421919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase.
    Leslie NR; Gray A; Pass I; Orchiston EA; Downes CP
    Biochem J; 2000 Mar; 346 Pt 3(Pt 3):827-33. PubMed ID: 10698713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute regulation of the tumour suppressor phosphatase, PTEN, by anionic lipids and reactive oxygen species.
    Downes CP; Walker S; McConnachie G; Lindsay Y; Batty IH; Leslie NR
    Biochem Soc Trans; 2004 Apr; 32(Pt 2):338-42. PubMed ID: 15046604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic switching of PI3K-dependent lipid signals.
    Downes CP; Leslie NR; Batty IH; van der Kaay J
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):188-92. PubMed ID: 17371235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of the PTEN phosphatase.
    Gericke A; Munson M; Ross AH
    Gene; 2006 Jun; 374():1-9. PubMed ID: 16675164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity.
    Meuillet EJ; Mahadevan D; Berggren M; Coon A; Powis G
    Arch Biochem Biophys; 2004 Sep; 429(2):123-33. PubMed ID: 15313215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway.
    Weng LP; Brown JL; Baker KM; Ostrowski MC; Eng C
    Hum Mol Genet; 2002 Jul; 11(15):1687-96. PubMed ID: 12095911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.
    Maehama T; Dixon JE
    J Biol Chem; 1998 May; 273(22):13375-8. PubMed ID: 9593664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SHIP-2 and PTEN are expressed and active in vascular smooth muscle cell nuclei, but only SHIP-2 is associated with nuclear speckles.
    Déléris P; Bacqueville D; Gayral S; Carrez L; Salles JP; Perret B; Breton-Douillon M
    J Biol Chem; 2003 Oct; 278(40):38884-91. PubMed ID: 12847108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of cell migration by the C2 domain of the tumor suppressor PTEN.
    Raftopoulou M; Etienne-Manneville S; Self A; Nicholls S; Hall A
    Science; 2004 Feb; 303(5661):1179-81. PubMed ID: 14976311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention.
    Steelman LS; Bertrand FE; McCubrey JA
    Expert Opin Ther Targets; 2004 Dec; 8(6):537-50. PubMed ID: 15584861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN: life as a tumor suppressor.
    Simpson L; Parsons R
    Exp Cell Res; 2001 Mar; 264(1):29-41. PubMed ID: 11237521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif.
    Walker SM; Leslie NR; Perera NM; Batty IH; Downes CP
    Biochem J; 2004 Apr; 379(Pt 2):301-7. PubMed ID: 14711368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN and myotubularin: novel phosphoinositide phosphatases.
    Maehama T; Taylor GS; Dixon JE
    Annu Rev Biochem; 2001; 70():247-79. PubMed ID: 11395408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding coincident signaling by PTEN through its inositol 1,3,4,5,6-pentakisphosphate 3-phosphatase activity.
    Caffrey JJ; Darden T; Wenk MR; Shears SB
    FEBS Lett; 2001 Jun; 499(1-2):6-10. PubMed ID: 11418101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphatidylinositol 3,4,5-trisphosphate modulation in SHIP2-deficient mouse embryonic fibroblasts.
    Blero D; Zhang J; Pesesse X; Payrastre B; Dumont JE; Schurmans S; Erneux C
    FEBS J; 2005 May; 272(10):2512-22. PubMed ID: 15885100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The termination of PI3K signalling by SHIP1 and SHIP2 inositol 5-phosphatases.
    Backers K; Blero D; Paternotte N; Zhang J; Erneux C
    Adv Enzyme Regul; 2003; 43():15-28. PubMed ID: 12791379
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.